

H g K g E cha ge a d Clea i g Limi ed a d The S ck E cha ge f H g K g  
Limi ed t ake e ibili f the c t e t f t hi a ceme t, make  
e e e t a i a t i acc ac c m l e e a d e e l di claim a liabili  
h t e e f a l h e e a i i g f m i elia ce the h le a  
a t f the c t e t f t hi a ceme t.



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
(深圳市海普瑞藥業集團股份有限公司)

(A c c a c a e d e P e e' R e b c f C a e d a b )  
(Stock code: 9989)

**VOLUNTARY ANNOUNCEMENT**  
**“EXARANE” OBTAINS APPROVAL FROM**  
**THAILAND**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Exarane (an enoxaparin sodium injection and one of the Group’s leading drugs) produced by Shenzhen Techdow Medicine Co., Ltd., a wholly-owned subsidiary of the Company, has been approved by Thailand Food and Drug Administration for sales in the market.

**DETAILS OF THE LICENSE**

(I) Product name: Enoxaparin sodium injection

(II) Dosage form: Solution for injection

(III) Strength: 0.2ml:20mg, 0.4ml:40mg, 0.6ml:60mg, 0.8ml:80mg

(IV) Indications:

1. 0.2ml:20mg and 0.4ml:40mg injections:

Prevention of venous thromboembolic diseases (prevention of venous thrombosis), especially thrombosis associated with orthopedic or general surgery.

2. 0.6ml:60mg and 0.8ml:80mg injections:

(1) Treatment of deep vein thrombosis, with or without pulmonary embolism, where clinical symptoms are not severe, except where pulmonary embolism requires surgical intervention or thrombolytic therapy. (2) In combination with aspirin for the treatment of unstable angina and non-Q wave myocardial infarction, and for the prevention of thrombus formation in extracorporeal circulation during blood dialysis. (3) In combination with thrombolytic agents or percutaneous coronary intervention (PCI) for the treatment of acute ST-segment elevation myocardial infarction.

(V) Validity period of the license: 7 years

### **BENEFIT AND IMPACT TO THE COMPANY**

This approval means that the Group's enoxaparin sodium finish dose will be sold in the Thailand market, further enhancing the Group's market share of enoxaparin sodium finish dose worldwide. We believe that this approval is another important achievement in the international layout of the Group's finish dose business, once again proving the Group's ability to enter overseas markets. In the future, the Group will continue to exert efforts to accelerate the Group's expansion into the global market and the construction of sales channels, laying the groundwork for further strengthening the development of overseas markets.

Announcement is hereby given.

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, PRC  
April 2, 2024

*At the date of this announcement, the executive directors of the Company are M. Li Li, M. Li Ta, M. Sha Y a d M. Zha g Pi g; and the independent non-executive directors of the Company are D. L Ch a, M. Wa g Pa g a d M. Yi Mi g.*